Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022

Rhea-AI Summary

Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to report its financial results for Q1 2022, ending March 31, on May 4, 2022. The announcement highlights the company’s progress in precision oncology. Following the report, a conference call will take place at 2:00 PM PT (5:00 PM ET) to discuss business performance. Rain specializes in developing therapies targeting oncogenic drivers, including its lead candidate, milademetan, an oral MDM2 inhibitor. This precision approach aims to select patients based on tumor genetics.

Positive

• Upcoming Q1 2022 financial results are expected to present recent progress.
• Development of milademetan, an oral inhibitor of MDM2, shows potential in precision oncology.

Negative

• None.

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of recent progress on Wednesday, May 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.

Conference Call and Webcast Details:
Date: May 4, 2022
Time: 2:00-3:00 pm PT (5:00-6:00 pm ET)
Dial In Numbers: 1 (877) 300-8521 (U.S. Toll Free) / 1 (412) 317-6026 (International)

Conference ID: 10166166

Webcast Link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=yOa8KoUv

Replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

When will Rain Therapeutics report its Q1 2022 financial results?

Rain Therapeutics will report its Q1 2022 financial results on May 4, 2022.

What is the significance of the milademetan drug developed by Rain?

Milademetan is an oral MDM2 inhibitor that targets oncogenic drivers, potentially offering new treatment options in oncology.

What time is the conference call for Rain Therapeutics' financial results?

The conference call will take place at 2:00 PM PT (5:00 PM ET) on May 4, 2022.

How can I access the replay of Rain Therapeutics' conference call?

The replay can be accessed on the Events section of the Rain website after the presentation.